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ndividualized Approach
o the Management of
oronary Heart Disease
dentifying the
onresponders Before It Is Too Late*
eter Ganz, MD, Priscilla Y. Hsue, MD
an Francisco, California
everal therapies have proven effective in the treatment of
oronary heart disease (CHD), primarily, 3-hydroxy-3-
ethylglutaryl-coenzyme A reductase inhibitors (statins),
ngiotensin-converting enzyme inhibitors, and antiplatelet
gents (aspirin, clopidogrel). The 20% to 40% reduction in
ardiovascular events achieved by each of these agents in
lacebo-controlled, randomized trials has been duly cele-
rated yet it leaves many patients unprotected. Among the
ighest risk CHD patients, namely, those presenting with
cute coronary syndromes, 7% will suffer a myocardial
nfarction (MI) or CHD death within 24 months of the
nitial presentation despite intensive treatment to recom-
ended guidelines (1). Thus, it is of utmost importance to
dentify individual patients who do not respond to therapy
efore adverse outcomes intervene. Several approaches to
his individualized medicine are in development, including
harmacogenetic testing, measurement of inflammatory
iomarkers, and assessment of endothelial function.
See page 323
harmacogenetics. Pharmacogenetics aims to identify the
enetic determinants of interindividual variability in re-
ponse to drugs (2). Pharmacogenetic approaches have been
uccessful at improving the efficacy and safety for only a few
rugs, with warfarin being the most prominent example in
ardiovascular medicine (3).
Although statins reduce the risk of CHD, there is also
ppreciable interindividual variability in plasma lipoprotein
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology and the Center of Excellence in Vascular
esearch, San Francisco General Hospital, University of California, San Francisco,
alifornia. Dr. Ganz is a consultant for Pfizer, GlaxoSmithKline, Genentech, andd
ristol-Myers Squibb (total $20,000/year), and is on the Speakers’ Bureau of Pfizer
$20,000/year).hanges and in cardiovascular outcomes. Polymorphisms in
enes affecting statin pharmacokinetics (e.g., in 3-hydroxy-
-methylglutaryl-coenzyme A reductase and apolipoprotein
) are associated with variable lipoprotein responses (4,5).
owever, these genetic effects are relatively modest (4,5).
urthermore, for pharmacogenetic approaches to add clin-
cal value, the genetic markers will need to predict cardio-
ascular outcomes and not just lipoprotein changes. Among
ntiplatelet agents, there is also substantial variability in
ffectiveness with up to 30% of subjects considered nonre-
ponders to aspirin and 25% nonresponders to clopidogrel
2). However, specific gene variants that predict the re-
ponses to aspirin or clopidogrel remain unknown. Cardio-
ascular medicine of the future will mostly likely include
argeted therapies based on personal genotypic information,
ut clearly much work remains to be done before this
appens on a significant scale (2).
nflammatory biomarkers. The inflammatory marker
-reactive protein (CRP) is the most extensively studied
nd the most robust predictor of cardiovascular events in
pparently healthy subjects and in patients with CHD.
reatment with statins reduces CRP compared with pla-
ebo by 15% to 50% (6–8). With statin treatment, greater
ecreases in CRP or lower achieved levels of CRP are
ssociated with reduced growth of coronary plaques in
atients with stable CHD (7) and more favorable clinical
utcomes of patients with acute coronary syndromes (6,8).
hile the reductions in CRP and low-density lipoprotein
holesterol (LDL-C) achieved with statins are both dose
ependent (9), the response in CRP cannot be predicted
rom the lowering of LDL-C (6–8). Thus, a logical
nference can be made for dual LDL-C and CRP goals for
HD patients, with adjustment of statin doses to achieve
oth. Whether or not dual low-density lipoprotein and
RP targets are justified in apparently healthy subjects
reated with statins will be surmised from the recently
ompleted JUPITER (Justification for the Use of Statins in
revention: An Intervention Trial Evaluating Rosuvastatin)
tudy (10). Committees preparing future guidelines should
ake note.
ndothelial function. Much progress has occurred in the
nderstanding of the biology of the endothelium since the
iscovery of endothelium-dependent vasodilation by Furch-
ott and Zawadzski in 1980 (11) and since our first
escription of endothelial function testing in humans in
986 (12). The endothelium plays a central role in the
egulation of vascular tone by releasing several vasodilator
ubstances, the key among them being nitric oxide (NO)
13–15). Nitric oxide also mediates many of the protective
unctions of the endothelium by limiting vascular inflam-
ation, vascular smooth muscle proliferation, platelet ag-
regation, and tissue factor production (13,14).
Endothelial dysfunction has been linked to virtually all
nown risk factors for atherosclerosis (16–18). It has been
etected in conduit arteries and in resistance arterioles and
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Management of CHD January 27, 2009:331–3n coronary as well as peripheral arteries (13–15). This
ecognition of endothelial dysfunction as a systemic disorder
as facilitated endothelial function testing in accessible
rteries, including flow-mediated dilation (FMD) in the
rachial artery (13,14).
Clinical investigations strongly support an antiathero-
enic role for NO. Coronary endothelial dysfunction in
ardiac transplant recipients is associated with progressive
ransplant vasculopathy (19). Numerous studies have shown
strong association between endothelial dysfunction and
ardiovascular events. Among nearly 2,500 patients with
ostly overt atherosclerosis derived from 10 studies and
ith a follow-up of 1 to 92 months, endothelial dysfunction
onferred a nearly 3-fold increase in cardiovascular event
ates (15). Endothelial dysfunction also independently pre-
icted adverse cardiovascular outcomes among apparently
ealthy elderly persons (18).
Commonly used therapies in the treatment of CHD
everse endothelial dysfunction, including drugs that modify
ipids and reduce blood pressure, along with smoking
essation, physical exercise, and dietary interventions
13,14,20). The observation in these studies that interven-
ions restored normal endothelial function in some subjects
ut failed to do so in others suggested that endothelial
unction testing may be able to differentiate therapeutic
esponders from nonresponders. Accordingly, Modena et al.
20) investigated prospectively 400 post-menopausal women
ith hypertension and a low prevalence of other risk factors
hose blood pressure was successfully reduced to 140/90
m Hg. The failure to restore endothelial function to normal
as associated with nearly a 7-fold increase in cardiovascular
vent rates during a mean 67 months of follow-up.
In this issue of the Journal, Kitta et al. (21) tested the
ypothesis that a change in endothelial function in response
o optimized medical therapy for CHD predicts cardiovas-
ular events. They studied 251 Japanese subjects with newly
iagnosed stable CHD who were not optimally treated, and
emonstrated impaired endothelial function in the brachial
rtery (defined as FMD 5.5%). Measurement of FMD
as repeated after 6 months of optimized, individualized
herapy including medications and life-style changes recom-
ended by American Heart Association/American College
f Cardiology guidelines. The target for LDL-C was 100
g/dl, hypertension control 140/90 mm Hg (or 130/80
m Hg if diabetes mellitus was present), and hemoglobin
1C7.0% for diabetic control. All patients were advised to
chieve waist circumference goals by a combination of
xercise and caloric intake. The second FMD test was
mpaired in 104 patients (41% of all study patients) despite
reatment. This continued impairment in FMD was not
elated to medication use or the frequencies with which
herapeutic targets were achieved. After the second FMD
est, all patients were followed up for as long as 36 months
mean 31  4 months) for cardiac death, nonfatal MI,
ngina pectoris requiring revascularization, or ischemic
troke. The results were striking: 26% of patients with
Fersistent endothelial dysfunction sustained a cardiovascular
vent compared with only 10% of patients with improved
ndothelial function. Persistently impaired endothelial
unction independently predicted future events with an
djusted hazard ratio of 2.9. Thus, persistent endothelial
ysfunction in the brachial artery despite 6 months of
tandard therapy for CHD indeed identified a cohort with
high residual risk.
The authors are to be congratulated on this thought-
rovoking study. Yet, it is only a first step among many
eeded to incorporate endothelial function testing in the
linical realm to monitor the effectiveness of therapies. The
reatment in this study was “optimized,” but was far from
ptimal. For example, only 60% of the patients in this study
eceived a statin at the second FMD test, not all patients
eached the LDL-C target of100 mg/dl, and only 20% of
atients were on beta-blocker medication. The composite
linical end point was driven by revascularizations and not
y the more rigorous end points of cardiac death and MIs.
hus, a larger study is now needed with defined treatment
lgorithms, rigorous therapeutic goals, and statistical power
o capture hard end points. In addition, the available
ethodologies of endothelial function testing are poorly
tandardized and, therefore, are not ready for widespread
linical application. Although the cutoff between normal
nd abnormal FMD in this study was 5.5%, it was 10% in
he study by Modena et al. (20). In 2,883 Framingham
eart Study participants ages 33 to 88 years, mean FMD in
his relatively healthy cohort was only 3.3% in women and
.4% in men (16).
Given this lack of agreement on what constitutes a
ormal result, standardization of the FMD method based
n age, sex, ethnicity, laboratory technique, and analysis will
e required. Other approaches to assessing endothelial
unction are still in development (13–15). When these
bstacles are overcome, rigorous biostatistical and phar-
acoeconomic methods will be essential to establish that
ndothelial function testing adds further value and cost
ffectiveness to the monitoring approaches we already em-
loy. Lastly, it is not yet known how the information from
ndothelial function testing would alter therapy (e.g., titra-
ion or addition of drugs or consideration of revasculariza-
ion) and whether any intensification of treatment guided by
ndothelial function testing would improve clinical out-
omes. Despite these hurdles, the study by Kitta et al. (21)
s an encouraging proof of principle. In the past, the lack of
atient-to-patient uniformity in the improvement in endo-
helial function with various therapies represented an “in-
onvenient truth.” In the future, reinforced with the much
eeded improvements we have outlined, it may lead to more
ffective, personalized treatments.
eprint requests and correspondence: Dr. Peter Ganz, San
rancisco General Hospital, 1001 Potrero Avenue, 5G1, San
rancisco, California 94110. E-mail: ganzp@medsfgh.ucsf.edu.
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